⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821046 | 0.93 | — | — | |
| SCHEMBL4146154 | 0.90 | — | — | |
| SCHEMBL4767244 | 0.90 | — | — | |
| SCHEMBL11502069 | 0.86 | CYP2D6 (0.32) | — | |
| SCHEMBL5709839 | 0.86 | — | — | |
| SCHEMBL10815925 | 0.75 | MC4R (0.41) | — | |
| SCHEMBL1363734 | 0.73 | — | — | |
| SCHEMBL10783067 | 0.73 | — | — | |
| SCHEMBL293089 | 0.73 | — | — | |
| SCHEMBL840178 | 0.72 | CHRNA7 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1914182-B | Quinazoline derivatives | ASTRAZENECA AB | 2011-09-07 | — | — | CN | disclosed |
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| EP-1713781-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| CN-1914182-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-02-14 | — | — | CN | disclosed |
| EP-1713781-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075439-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |